Mesoblast rallies on advisory committee Ryoncil nod

Mesoblast Limited (NASDAQ:MESO) jumps 45% premarket on increased volume on the heels of a 9-1 vote by an FDA advisory committee backing approval of Ryoncil (remestemcel-L) (ex-vivo culture-expanded adult human mesenchymal stromal cells suspension for intravenous infusion) for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

The FDA’s action date is September 30.

https://seekingalpha.com/news/3605644-mesoblast-rallies-45-on-advisory-committee-ryoncil-nod